In contrast to Korean, Chinese, and American patients, PMF and ET patients showed higher percentages of CALR mutations, estimated to range from 12.6% to 89%, compared to our study range of 7.3–14.3% [20,22,23]. The gene discussed is CALR; the disease is essential thrombocythemia.